Senate investigation uncovers 'bad actors' behind off-patent drug price gouging

22 December 2016
ussenate-big

The US Senate’s Special Committee on Aging has published a damning report on pharma companies’ manipulation of loopholes in the system so they can raise prices of off-patent drugs massively.

This report follows a bi-partisan investigation launched in November 2015 on abrupt and dramatic price increases in prescription drugs whose patents had long since expired.

"The companies had not invested a penny in research and development to create or to significantly improve the drugs"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical